Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.50 |
| ▸ | RAB9A | P51151 | 6/20 | 0.50 |
| ▸ | NPC1 | O15118 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | GAA | P10253 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.41 |
| ▸ | GABRP | O00591 | 1/20 | 0.41 |
| ▸ | GABRD | O14764 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL743243 | 0.81 | — | — | |
| SCHEMBL4474111 | 0.72 | CNR1 (0.39) | RAB9ANPC1ALDH1A1KMT2ACYP2C19 | |
| SCHEMBL969213 | 0.71 | MEN1 (0.51) | MAPTALDH1A1CYP1A2MEN1KMT2A | |
| SCHEMBL1444391 | 0.71 | — | — | |
| SCHEMBL17028993 | 0.70 | ALDH1A1 (0.46) | MAPTRAB9ANPC1ALDH1A1SMN1; SMN2 | |
| SCHEMBL971952 | 0.70 | ALDH1A1 (0.44) | MAPTRAB9ANPC1ALDH1A1CYP1A2 | |
| SCHEMBL243257 | 0.70 | MAPT (0.50) | MAPTRAB9ANPC1ALDH1A1CYP1A2 | |
| SCHEMBL13144514 | 0.70 | MAPT (0.70) | MAPTRAB9ANPC1ALDH1A1CYP1A2 | |
| SCHEMBL3702158 | 0.70 | MAPT (0.61) | MAPTRAB9ANPC1ALDH1A1CYP1A2 | |
| SCHEMBL914552 | 0.70 | RAB9A (0.68) | MAPTRAB9ANPC1ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 221 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118344265-A | Amide compound and preparation method and application thereof | 河北大学 | 2024-07-16 | — | — | CN | claimed |
| EP-2668183-B1 | IL17 AND IFN-GAMMA INHIBITION FOR THE TREATMENT OF AUTOIMMUNE INFLAMMATION | 4SC DISCOVERY GMBH (DE) | 2017-11-01 | — | — | EP | claimed |
| US-9238658-B2 | Substituted piperidinyl-carboxamide derivatives useful as SCD 1 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2016-01-19 | — | — | US | claimed |
| CN-103459385-B | IL17 and the IFN-γ being used for the treatment of autoimmune inflammation suppresses | 4SC DISCOVERY GMBH (DE) | 2015-08-05 | — | — | CN | claimed |
| CN-104206385-A | Use of amine compound as bactericide | SINOCHEM CORP | 2014-12-17 | — | — | CN | claimed |
| US-20140364393-A1 | SUBSTITUTED PIPERIDINYL-CARBOXAMIDE DERIVATIVES USEFUL AS SCD 1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-12-11 | — | — | US | claimed |
| CN-103459385-A | IL17 and IFN-[gamma] inhibition for the treatment of autoimmune inflammation | 4SC DISCOVERY GMBH | 2013-12-18 | — | — | CN | claimed |
| WO-2013085954-A1 | SUBSTITUTED PIPERIDINYL-CARBOXAMIDE DERIVATIVES USEFUL AS SCD 1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2013-06-13 | — | — | WO | claimed |
| CN-102942565-A | 3,4-dichloro isothiazole derivatives, their preparation method and application | JIANGXI TIANREN ECOLOGY CO LTD | 2013-02-27 | — | — | CN | claimed |
| US-8354436-B2 | IL17 and IFN-gamma inhibition for the treatment of autoimmune inflammation | 4SC DISCOVERY GMBH (DE) | 2013-01-15 | — | — | US | claimed |
| US-6262103-B1 | ALZHEIMER'S DISEASE. | MERCK SHARP & DOHME LIMITED (GB) | 2001-07-17 | — | — | US | claimed |
| JP-2001503408-A | — | — | 2001-03-13 | — | — | JP | claimed |
| EP-0937072-A1 | THIENYLCYCLOHEXANONE DERIVATIVES AS LIGANDS OF THE GABA A? $g(a)5 RECEPTOR SUBTYPE | MERCK SHARP & DOHME LTD. (GB) | 1999-08-25 | — | — | EP | claimed |
| WO-1998018792-A1 | THIENYLCYCLOHEXANONE DERIVATIVES AS LIGANDS OF THE GABAA α5 RECEPTOR SUBTYPE | MERCK SHARP & DOHME LIMITED (GB) | 1998-05-07 | — | — | WO | claimed |
| US-5158598-A | Insecticides, miticides, and nematocides; nonphytotoxic | BASF AKTIENGESELLSCHAFT (DE) | 1992-10-27 | — | — | US | claimed |
| EP-0248735-B1 | 2-Thiazolyl imidazo [1,2-a] pyrimidines and their salts, process for their preparation, their use as medicaments and compositions containing them | ROUSSEL-UCLAF (FR) | 1990-05-23 | — | — | EP | claimed |
| US-4925846-A | COGNITION ACTIVATORS, TRANQUILIZERS, DIETETICS | ROUSSEL UCLAF (FR) | 1990-05-15 | — | — | US | claimed |
| US-4829053-A | Amino acid derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1989-05-09 | — | — | US | claimed |
| EP-0248735-A1 | 2-Thiazolyl imidazo [1,2-a] pyrimidines and their salts, process for their preparation, their use as medicaments and compositions containing them | ROUSSEL-UCLAF (FR) | 1987-12-09 | — | — | EP | claimed |
| US-4243669-A | ANTICOAGULANTS | BEECHAM GROUP LIMITED (GB) | 1981-01-06 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140364393-A1 | SUBSTITUTED PIPERIDINYL-CARBOXAMIDE DERIVATIVES USEFUL AS SCD 1 INHIBITORS | SCD, SCD5, FASN | MAPT 4508/4885RAB9A 2991/4885NPC1 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.